Poseida Therapeutics (PSTX) – PRNewswire
-
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
-
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
-
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
-
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
-
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
-
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
-
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
-
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones
-
Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) An
-
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
-
Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition
-
Poseida Therapeutics Announces Leadership Transition
-
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
-
Poseida Therapeutics Provides Financial Results for the Second Quarter of 2023
-
Poseida Therapeutics Announces Strategic Investment by Astellas and Provides Business Update
-
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida's Commitment to Redefining Cancer Cell Therapy
-
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-CD19CD20-ALLO1, an Allogeneic Dual CAR-T Cell Therapy for B-Cell Malignancies
-
Poseida Therapeutics to Join Russell 3000® and Russell 2000® Indexes
-
Poseida Therapeutics Announces Virtual 2023 Annual Meeting of Stockholders
-
Poseida Therapeutics to Present at Stifel 2023 Tailoring Genes: Genetic Medicines Day
-
Poseida Therapeutics to Present at 31st Congress of the International Society on Thrombosis and Haemostasis
-
Poseida Therapeutics Presents Encouraging Preclinical Data Across its Gene Therapy Programs at the American Society for Gene and Cell Therapy 2023 Annual Meeting
-
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2023
-
Poseida Therapeutics Announces Multiple Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting
-
Poseida Therapeutics to Present at BofA Securities 2023 Health Care Conference
-
Poseida Therapeutics Appoints Rafael G. Amado, M.D., to Board of Directors
-
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Poseida Therapeutics Appoints Kristin Yarema, Ph.D., as President, Cell Therapy
-
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2022
-
Poseida Therapeutics Appoints Five New Members to Its Gene Therapy Scientific Advisory Board
-
Poseida Therapeutics Hosts Third Annual Virtual R&D Day Highlighting Novel Pipeline Assets and Latest Technology Innovations
-
Poseida Therapeutics to Present at H.C. Wainwright Cell Therapy Virtual Conference
-
Poseida Therapeutics to Host Third Annual Virtual R&D Day on February 22, 2023
-
Poseida Therapeutics Announces Board Change
-
Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition
-
Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress
-
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022
-
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
-
Poseida Therapeutics to Present at the ESMO Immuno-Oncology 2022 Annual Congress
-
Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition
-
Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting
-
Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
-
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022
-
Poseida Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Poseida Therapeutics Announces Pricing of Public Offering of Common Stock
-
Poseida Therapeutics Announces Proposed Public Offering of Common Stock
-
Poseida Therapeutics Announces Proposed Public Offering of Common Stock
-
Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies
Back to PSTX Stock Lookup
